Scarica l'app Stockscreener
3.12
1.30%
0.04
Dopo l'orario di chiusura:
3.12
Turn Therapeutics Inc Borsa (TTRX) Ultime notizie
Can Black Diamond Therapeutics (BDTX) Turn Silevertinib’s Dual-Cancer Ambition Into a Cohesive Strategy? - Yahoo Finance
Arthur Golden Increases Stake in Turn Therapeutics Inc with Rece - GuruFocus
Golden Arthur F buys Turn Therapeutics shares worth $33945 By Investing.com - Investing.com Nigeria
Golden Arthur F buys Turn Therapeutics shares worth $33945 - Investing.com
Turn Therapeutics Director Arthur F Golden Acquires 9,868 Shares - TradingView
Dir Golden Buys 9,868 ($33.9K) Of Turn Therapeutics Inc [TTRX] - TradingView
Insider Buying: Arthur Golden Acquires Additional Shares of Turn Therapeutics Inc (TTRX) - GuruFocus
Turn Therapeutics Director Arthur F. Golden Acquires 20,532 Shares - TradingView
Dir Golden Buys 20,532 ($58.9K) Of Turn Therapeutics Inc [TTRX] - TradingView
[Form 4] Turn Therapeutics Inc. Insider Trading Activity - Stock Titan
Turn Therapeutics Inc. Common Stock trading resumes - MSN
Zuraiz Chaudhary buys Turn Therapeutics (TTRX) shares worth $9,050 By Investing.com - Investing.com Nigeria
Zuraiz Chaudhary buys Turn Therapeutics (TTRX) shares worth $9,050 - Investing.com
Do US FDA Complete Response Letters Suggest Turn To Less Flexibility In Rare Disease? - Citeline News & Insights
Turn Therapeutics (TTRX) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Turn Therapeutics’ GX-03 Recognized for Dermatology Innovation - MSN
Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - The Manila Times
Turn Therapeutics GX-03 Technology Named as One of Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment by Patient Care Online Magazine - MarketScreener
Turn Therapeutics (Nasdaq: TTRX) features Dr. Robert Redfield on trust in science - Stock Titan
Turn Therapeutics’ GX-03 Technology Named as One of 'Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine - The Manila Times
Turn (NASDAQ: TTRX) named among five novel eczema mechanisms by Patient Care Online - Stock Titan
Turn Therapeutics appoints Andrew Scott as VP of Corporate Communications - Investing.com Australia
Turn Therapeutics Appoints New VP of Communications - TipRanks
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications - The Globe and Mail
Turn Therapeutics appoints Andrew Scott as VP of Corporate Communications By Investing.com - Investing.com South Africa
Turn Therapeutics Appoints Veteran Capital Markets - GlobeNewswire
Turn Therapeutics (NASDAQ: TTRX) names Andrew Scott VP of Corporate Communications; 30 years - Stock Titan
Turn Therapeutics launches webinar series for shareholder engagement - MSN
Jennifer Doudna spinoff aims to turn patients’ immune cells into CAR-T fighters with single shot - statnews.com
Turn Therapeutics Inc (TTRX) Stock News Today - TipRanks
Turn Therapeutics files to sell 7M shares off common stock for holders - MSN
TTRX News Today | Why did Turn Therapeutics stock drop today? - MarketBeat
Turn Therapeutics (TTRX) Stock Trends and Sentiment 2025 - MarketBeat
Turn Therapeutics (TTRX) Competitors and Alternatives 2025 - MarketBeat
Turn Therapeutics (TTRX) 10K Form and SEC Filings 2025 - MarketBeat
Turn Therapeutics signs license deal with surgical product supplier Medline - MSN
Turn Therapeutics partners with Medline for global supply agreement By Investing.com - Investing.com Australia
Turn Therapeutics Partners with Medline for Global Expansion - TipRanks
Turn Therapeutics (NASDAQ: TTRX) teams with Medline to commercialize PermaFusion products - Stock Titan
Turn Therapeutics (TTRX) Stock Price, News & Analysis - MarketBeat
Turn Therapeutics (NASDAQ:TTRX) Insider Purchases $65,715.60 in Stock - Defense World
Turn Therapeutics appoints Kester to board of directors - MSN
Form 424B5 Turn Therapeutics Inc. - StreetInsider
What is the current Price Target and Forecast for Turn Therapeutics Inc. (TTRX) - Zacks Investment Research
Should I buy Turn Therapeutics Inc. (TTRX) - Zacks Investment Research
0.39%
1.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):